Early observations and pilot data that first suggested a new direction
Traditional brain tumor surgery under general anesthesia relied on anatomical landmarks alone, with limited ability to assess functional boundaries intraoperatively. Penfield's pioneering cortical stimulation work from the 1930s-1950s established that eloquent cortex could be mapped in awake patients, but the technique remained niche. Retrospective series in the 1990s from Berger, Duffau, and others demonstrated that direct cortical and subcortical stimulation mapping during awake craniotomy could identify functional boundaries in real time, enabling more aggressive resection of gliomas near eloquent cortex while preserving neurological function. These early series showed lower rates of permanent neurological deficit compared to historical controls operated under general anesthesia alone.
Landmark RCTs and pivotal trials that established the evidence base
A pivotal RCT by De Witt Hamer and colleagues demonstrated that awake craniotomy with intraoperative stimulation mapping significantly reduced the rate of late severe neurological deficits compared to surgery under general anesthesia (3.4% vs 8.2%) while achieving comparable or superior extent of resection. The systematic review and meta-analysis by De Witt Hamer (2012) of 8,091 patients confirmed that intraoperative stimulation mapping was associated with fewer late severe neurological deficits. Separately, Stummer's landmark 5-ALA fluorescence-guided surgery trial (2006) proved that visualizing tumor margins with fluorescence during glioblastoma surgery doubled the rate of complete resection (65% vs 36%) and improved progression-free survival, providing a complementary tool for maximizing resection extent.
Follow-up studies, subgroup analyses, and real-world validation
Intraoperative MRI (iMRI) was introduced as another tool to maximize extent of resection, with the INFORM trial and other studies demonstrating that iMRI-guided resection could increase gross total resection rates. The combination of awake mapping, 5-ALA fluorescence, and iMRI created a multimodal approach to maximize safe resection. Growing evidence from large cohort studies established that extent of resection is a strong independent predictor of overall survival in both low-grade and high-grade gliomas, providing the oncological rationale for aggressive but function-preserving surgical strategies. Advances in brain plasticity research by Duffau revealed that repeated awake surgeries could leverage neural reorganization, allowing resection of areas previously considered inoperable.
Integration into clinical practice guidelines and recommendations
EANO (European Association of Neuro-Oncology) guidelines for low-grade gliomas recommend maximal safe resection as the primary treatment goal, with awake surgery and functional mapping recommended for tumors in or near eloquent areas. The NCCN Central Nervous System Cancers guidelines endorse the use of 5-ALA fluorescence-guided surgery for high-grade gliomas and recommend considering intraoperative mapping techniques to maximize safe resection. The Society for Neuro-Oncology and EANO joint guidelines emphasize that extent of resection is a modifiable prognostic factor that should be optimized through available intraoperative technologies.
EANO
Maximum safe resection is recommended for diffuse low-grade gliomas; awake surgery with cortical and subcortical mapping should be used for tumors in eloquent areas
NCCN
Consider 5-ALA fluorescence-guided surgery and intraoperative mapping to maximize extent of resection in gliomas
Now
Current standard of care and ongoing research directions
Awake craniotomy with cortical and subcortical stimulation mapping is now considered standard of care for gliomas in or near eloquent cortex at high-volume neuro-oncology centers. The multimodal surgical approach combining awake mapping, 5-ALA fluorescence, neuronavigation, and sometimes intraoperative MRI represents the current state of the art. Ongoing research focuses on connectome-based preoperative planning using advanced diffusion MRI, augmented reality visualization, machine learning prediction of functional boundaries, and supramaximal resection strategies for low-grade gliomas. The concept of the oncological-functional balance — maximizing tumor removal while preserving quality of life — remains the guiding principle of modern glioma surgery.
Awake craniotomy has a well-established safety profile at experienced centers. Failure to complete the awake portion occurs in approximately 2-5% of cases, usually due to patient anxiety or seizures. Modern anesthetic protocols using scalp blocks, sedation-awake-sedation techniques, and experienced neuroanesthesia teams have made the procedure well-tolerated. Patients typically report less pain and faster recovery than expected.
Does extent of resection matter for survival in gliomas?+
Multiple large cohort studies demonstrate that greater extent of resection is independently associated with longer overall survival and progression-free survival in both low-grade and high-grade gliomas. For glioblastoma, gross total resection improves median survival by several months. For low-grade gliomas, aggressive resection beyond the FLAIR signal abnormality (supramaximal resection) may further delay malignant transformation.
What is 5-ALA and how does it help in brain tumor surgery?+
5-aminolevulinic acid (5-ALA) is an orally administered agent that is metabolized to a fluorescent compound (protoporphyrin IX) preferentially accumulated in high-grade glioma cells. Under violet-blue light, tumor tissue fluoresces pink while normal brain does not. The Stummer 2006 RCT showed this doubles complete resection rates from 36% to 65% and improves progression-free survival. It is now widely used for high-grade glioma surgery but is less reliable for low-grade tumors.
